These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 35622602

  • 1. Structural Features of Clostridium botulinum Neurotoxin Subtype A2 Cell Binding Domain.
    Gregory KS, Mahadeva TB, Liu SM, Acharya KR.
    Toxins (Basel); 2022 May 19; 14(5):. PubMed ID: 35622602
    [Abstract] [Full Text] [Related]

  • 2. A Comprehensive Structural Analysis of Clostridium botulinum Neurotoxin A Cell-Binding Domain from Different Subtypes.
    Gregory KS, Acharya KR.
    Toxins (Basel); 2023 Jan 18; 15(2):. PubMed ID: 36828407
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Crystal Structures of the Clostridium botulinum Neurotoxin A6 Cell Binding Domain Alone and in Complex with GD1a Reveal Significant Conformational Flexibility.
    Gregory KS, Newell AR, Mojanaga OO, Liu SM, Acharya KR.
    Int J Mol Sci; 2022 Aug 25; 23(17):. PubMed ID: 36077016
    [Abstract] [Full Text] [Related]

  • 7. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains.
    Davies JR, Rees J, Liu SM, Acharya KR.
    J Struct Biol; 2018 May 25; 202(2):113-117. PubMed ID: 29288126
    [Abstract] [Full Text] [Related]

  • 8. Structural and Biochemical Characterization of Botulinum Neurotoxin Subtype B2 Binding to Its Receptors.
    Davies JR, Masuyer G, Stenmark P.
    Toxins (Basel); 2020 Sep 17; 12(9):. PubMed ID: 32957706
    [Abstract] [Full Text] [Related]

  • 9. Entry of Botulinum Neurotoxin Subtypes A1 and A2 into Neurons.
    Kroken AR, Blum FC, Zuverink M, Barbieri JT.
    Infect Immun; 2017 Jan 17; 85(1):. PubMed ID: 27795365
    [Abstract] [Full Text] [Related]

  • 10. The Light Chain Defines the Duration of Action of Botulinum Toxin Serotype A Subtypes.
    Pellett S, Bradshaw M, Tepp WH, Pier CL, Whitemarsh RCM, Chen C, Barbieri JT, Johnson EA.
    mBio; 2018 Mar 27; 9(2):. PubMed ID: 29588398
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Crystal Structure of Botulinum Neurotoxin A2 in Complex with the Human Protein Receptor SV2C Reveals Plasticity in Receptor Binding.
    Gustafsson R, Zhang S, Masuyer G, Dong M, Stenmark P.
    Toxins (Basel); 2018 Apr 12; 10(4):. PubMed ID: 29649119
    [Abstract] [Full Text] [Related]

  • 13. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.
    Shi DY, Lu JS, Mao YY, Liu FJ, Wang R, Du P, Yu S, Yu YZ, Yang ZX.
    Appl Microbiol Biotechnol; 2023 May 12; 107(10):3205-3216. PubMed ID: 37058230
    [Abstract] [Full Text] [Related]

  • 14. Characterization of a highly neutralizing single monoclonal antibody to botulinum neurotoxin type A.
    Brier S, Rasetti-Escargueil C, Wijkhuisen A, Simon S, Marechal M, Lemichez E, Popoff MR.
    FASEB J; 2021 May 12; 35(5):e21540. PubMed ID: 33817838
    [Abstract] [Full Text] [Related]

  • 15. Enhancing toxin-based vaccines against botulism.
    Przedpelski A, Tepp WH, Zuverink M, Johnson EA, Pellet S, Barbieri JT.
    Vaccine; 2018 Feb 01; 36(6):827-832. PubMed ID: 29307477
    [Abstract] [Full Text] [Related]

  • 16. Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.
    Weisemann J, Stern D, Mahrhold S, Dorner BG, Rummel A.
    Toxins (Basel); 2016 May 17; 8(5):. PubMed ID: 27196927
    [Abstract] [Full Text] [Related]

  • 17. Purification and Characterization of Botulinum Neurotoxin FA from a Genetically Modified Clostridium botulinum Strain.
    Pellett S, Tepp WH, Bradshaw M, Kalb SR, Dykes JK, Lin G, Nawrocki EM, Pier CL, Barr JR, Maslanka SE, Johnson EA.
    mSphere; 2016 May 17; 1(1):. PubMed ID: 27303710
    [Abstract] [Full Text] [Related]

  • 18. Variations in the Botulinum Neurotoxin Binding Domain and the Potential for Novel Therapeutics.
    Davies JR, Liu SM, Acharya KR.
    Toxins (Basel); 2018 Oct 20; 10(10):. PubMed ID: 30347838
    [Abstract] [Full Text] [Related]

  • 19. Crystal structure of the BoNT/A2 receptor-binding domain in complex with the luminal domain of its neuronal receptor SV2C.
    Benoit RM, Schärer MA, Wieser MM, Li X, Frey D, Kammerer RA.
    Sci Rep; 2017 Mar 02; 7():43588. PubMed ID: 28252640
    [Abstract] [Full Text] [Related]

  • 20. Structural insights into the functional role of the Hcn sub-domain of the receptor-binding domain of the botulinum neurotoxin mosaic serotype C/D.
    Zhang Y, Gardberg AS, Edwards TE, Sankaran B, Robinson H, Varnum SM, Buchko GW.
    Biochimie; 2013 Jul 02; 95(7):1379-85. PubMed ID: 23523511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.